Pulmonary Vasculitis

Chapter

Abstract

Pulmonary vasculitis is usually but one manifestation of a systemic autoimmune disease. Primary vasculitis syndromes commonly affecting the respiratory tract are Wegener’s granulomatosis (WG), microscopic polyangiitis (MPA), and the Churg–Strauss syndrome. They are small-vessel vasculitides characterized by the presence of antineutrophil cytoplasmic autoantibodies (ANCA). This chapter provides an overview for a diagnostic approach to these patients that enables disease severity-adapted therapy. The respiratory manifestations of other vasculitides including Takayasu’s arteritis, Behcet’s disease, and Goodpasture’s disease are also discussed.

Keywords

Pulmonary vasculitis Wegener’s granulomatosis Microscopic polyangiitis Churg–Strauss syndrome Antineutrophil cytoplasmic autoantibodies 

References

  1. 1.
    Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.PubMedGoogle Scholar
  2. 2.
    Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134: 1033–42.PubMedGoogle Scholar
  3. 3.
    Watts RA, Scott DG. Epidemiology of the vasculitides. Semin Respir Crit Care Med. 2004;25:455–64.PubMedGoogle Scholar
  4. 4.
    Hoffman GS, Specks U. Anti-neutrophil cytoplasmic antibodies. Arthritis Rheum. 1998;41:1521–37.PubMedGoogle Scholar
  5. 5.
    Wiesner O, Russell KA, Lee AS, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum. 2004;50: 2954–65.PubMedGoogle Scholar
  6. 6.
    Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000;43: 414–9.PubMedGoogle Scholar
  7. 7.
    Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488–98.PubMedGoogle Scholar
  8. 8.
    Colby TV, Specks U. Wegener’s granulomatosis in the 1990s – a pulmonary pathologist’s perspective. Monogr Pathol. 1993;36:195–218.PubMedGoogle Scholar
  9. 9.
    Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000;43:1021–32.PubMedGoogle Scholar
  10. 10.
    Rasmussen N. Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist’s perspective. Curr Opin Rheumatol. 2001;13:3–11.PubMedGoogle Scholar
  11. 11.
    Cannady SB, Batra PS, Koening C, et al. Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. Laryngoscope. 2009;119:757–61.PubMedGoogle Scholar
  12. 12.
    Daum DE, Specks U, Colby TV, et al. Tracheobronchial involvement in Wegener’s granulomatosis. Am J Respir Crit Care Med. 1995;151:522–6.PubMedGoogle Scholar
  13. 13.
    Polychronopoulos VS, Prakash UB, Golbin JM, Edell ES, Specks U. Airway involvement in Wegener’s granulomatosis. Rheum Dis Clin North Am. 2007;33:755–75.PubMedGoogle Scholar
  14. 14.
    Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthritis Rheum. 1996;39:1754–60.PubMedGoogle Scholar
  15. 15.
    Ernst A, Rafeq S, Boiselle P, et al. Relapsing polychondritis and airway involvement. Chest. 2009;135: 1024–30.PubMedGoogle Scholar
  16. 16.
    Lee AS, Specks U. Pulmonary capillaritis. Semin Respir Crit Care Med. 2004;25:547–55.PubMedGoogle Scholar
  17. 17.
    Schnabel A, Reuter M, Csernok E, Richter C, Gross WL. Subclinical alveolar bleeding in pulmonary vasculitides: correlation with indices of disease activity. Eur Respir J. 1999;14:118–24.PubMedGoogle Scholar
  18. 18.
    de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006;17:2264–74.PubMedGoogle Scholar
  19. 19.
    Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurologic involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol. 1993;33:4–9.PubMedGoogle Scholar
  20. 20.
    de Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol. 2001;58:1215–21.PubMedGoogle Scholar
  21. 21.
    Harper SL, Letko E, Samson CM, et al. Wegener’s granulomatosis: the relationship between ocular and systemic disease. J Rheumatol. 2001;28:1025–32.PubMedGoogle Scholar
  22. 22.
    Daoud MS, Gibson LE, DeRemee RA, el-Azhary RA, Su WPD. Cutaneous Wegener’s granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. J Am Acad Dermatol. 1994;31:605–12.PubMedGoogle Scholar
  23. 23.
    Godman GC, Churg J. Wegener’s granulomatosis. Pathology and review of the literature. AMA Arch Path. 1954;58:533–53.Google Scholar
  24. 24.
    Carrington CB, Liebow AA. Limited forms of angiitis and granulomatosis of Wegener’s type. Am J Med. 1966;41:497–527.PubMedGoogle Scholar
  25. 25.
    DeRemee RA, McDonald TJ, Harrison EG, Coles DT. Wegener’s granulomatosis. Anatomic correlates, a proposed classification. Mayo Clin Proc. 1975;51: 777–81.Google Scholar
  26. 26.
    Fienberg R. The protracted superficial phenomenon in pathergic (Wegener’s) granulomatosis. Hum Pathol. 1980;12:458–67.Google Scholar
  27. 27.
    Stone JH. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum. 2003;48:2299–309.PubMedGoogle Scholar
  28. 28.
    Nölle B, Specks U, Lüdemann J, Rohrbach MS, DeRemee RA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value. Ann Int Med. 1989;111:28–40.PubMedGoogle Scholar
  29. 29.
    Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007;120:643.e9–14.Google Scholar
  30. 30.
    Travis WD. Common and uncommon manifestations of Wegener’s granulomatosis. Cardiovasc Pathol. 1994;3:217–25.Google Scholar
  31. 31.
    Maskell GF, Lockwood CM, Flower CDR. Computed tomography of the lung in Wegener’s granulomatosis. Clin Radiol. 1993;48:377–80.PubMedGoogle Scholar
  32. 32.
    Summers RM, Aggarwal NR, Sneller MC, et al. CT virtual bronchoscopy of the central airways in patients with Wegener’s granulomatosis. Chest. 2002;121:242–50.PubMedGoogle Scholar
  33. 33.
    Muhle C, Reinhold-Keller E, Richter C, et al. MRI of the nasal cavity, the paranasal sinuses and orbits in Wegener’s granulomatosis. Eur Radiol. 1997;7:566–70.PubMedGoogle Scholar
  34. 34.
    Walton EW. Giant-cell granuloma of the respiratory tract (Wegener’s granulomatosis). Br Med J. 1958;2: 265–70.PubMedGoogle Scholar
  35. 35.
    Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.PubMedGoogle Scholar
  36. 36.
    The WGET Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352:351–61.Google Scholar
  37. 37.
    Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790–803.PubMedGoogle Scholar
  38. 38.
    de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670–80.PubMedGoogle Scholar
  39. 39.
    Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 2001;44:2836–40.PubMedGoogle Scholar
  40. 40.
    Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:262–8.PubMedGoogle Scholar
  41. 41.
    Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006;173:180–7.PubMedGoogle Scholar
  42. 42.
    Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Eng J Med. 2010;363(3):221–32.Google Scholar
  43. 43.
    De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461–9.PubMedGoogle Scholar
  44. 44.
    Villa-Forte A, Clark TM, Gomes M, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore). 2007;86:269–77.Google Scholar
  45. 45.
    Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener’s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum. 1999;42:2666–73.PubMedGoogle Scholar
  46. 46.
    Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract. 2006;102: c100–7.PubMedGoogle Scholar
  47. 47.
    DeRemee RA, McDonald TJ, Weiland LH. Wegener’s granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc. 1985;60:27–32.PubMedGoogle Scholar
  48. 48.
    Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. N Engl J Med. 1996;335: 16–20.PubMedGoogle Scholar
  49. 49.
    Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med. 2000;93: 433–9.Google Scholar
  50. 50.
    Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58:308–17.PubMedGoogle Scholar
  51. 51.
    Rossi F, Jayne DR, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol. 1991;83:298–303.PubMedGoogle Scholar
  52. 52.
    Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003;42:1149–53.PubMedGoogle Scholar
  53. 53.
    Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180–8.PubMedGoogle Scholar
  54. 54.
    Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener’s Granulomatosis Etanercept Trial. Arthritis Rheum. 2006;54:1608–18.PubMedGoogle Scholar
  55. 55.
    Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology (Oxford). 2002;41:1303–7.Google Scholar
  56. 56.
    Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford). 2002;41:1126–32.Google Scholar
  57. 57.
    Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004;15:717–21.PubMedGoogle Scholar
  58. 58.
    Golbin JM, Keogh KA, Fervenza FC, Ytterberg SR, Specks U. Update on Rituximab use in patients with chronically relapsing Wegener’s Granulomatosis. Clin Exp Rheumatol. 2007;25:S-111.Google Scholar
  59. 59.
    Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60:2156–68.PubMedGoogle Scholar
  60. 60.
    Hernandez-Rodriguez J, Hoffman GS, Koening CL. Surgical interventions and local therapy for Wegener’s granulomatosis. Curr Opin Rheumatol. 2010;22: 29–36.PubMedGoogle Scholar
  61. 61.
    Congdon D, Sherris DA, Specks U, McDonald T. Long-term follow-up of repair of external nasal deformities in patients with Wegener’s granulomatosis. Laryngoscope. 2002;112:731–7.PubMedGoogle Scholar
  62. 62.
    Hoffman GS, Thomas-Golbanov CK, Chan J, Akst LM, Eliachar I. Treatment of subglottic stenosis, due to Wegener’s granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol. 2003;30: 1017–21.PubMedGoogle Scholar
  63. 63.
    Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42: 421–30.PubMedGoogle Scholar
  64. 64.
    Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in ­systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore). 2005;84:115–28.Google Scholar
  65. 65.
    Lauque D, Cadranel J, Lazor R, et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Medicine (Baltimore). 2000;79:222–33.Google Scholar
  66. 66.
    Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:23–32.PubMedGoogle Scholar
  67. 67.
    Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:33–9.PubMedGoogle Scholar
  68. 68.
    Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant. 2008;23:1307–12.PubMedGoogle Scholar
  69. 69.
    Silva F, Specks U, Kalra S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement – a prospective, open-label pilot trial. Clin J Am Soc Nephrol. 2010;5(3):445–53.PubMedGoogle Scholar
  70. 70.
    Watts RA, Jolliffe VA, Carruthers DM, Lockwood M, Scott DGI. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum. 1996;39:1208–12.PubMedGoogle Scholar
  71. 71.
    Nick J, Tuder R, May R, Fisher J. Polyarteritis nodosa with pulmonary vasculitis. Am J Respir Crit Care Med. 1996;153:450–3.PubMedGoogle Scholar
  72. 72.
    Guillevin L, Lhote F. Distinguishing polyarteritis nodosa from microscopic polyangiitis and implications for treatment. Curr Opin Rheumatol. 1995;7: 20–4.PubMedGoogle Scholar
  73. 73.
    Guillevin L, Lhote F, Amouroux J, Gherardi R, Callard P, Casassus P. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis Nodosa Group. Br J Rheumatol. 1996;35:958–64.PubMedGoogle Scholar
  74. 74.
    Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine. 1984;63:65–81.PubMedGoogle Scholar
  75. 75.
    Keogh KA, Specks U. Churg-Strauss syndrome. clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115:284–90.PubMedGoogle Scholar
  76. 76.
    Churg A, Brallas M, Cronin SR, Churg J. Formes frustes of Churg-Strauss syndrome. Chest. 1995;108: 320–3.PubMedGoogle Scholar
  77. 77.
    Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine. 1999;78:26–37.PubMedGoogle Scholar
  78. 78.
    Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52:2926–35.PubMedGoogle Scholar
  79. 79.
    Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143: 632–8.PubMedGoogle Scholar
  80. 80.
    Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis. 2006;47:770–9.PubMedGoogle Scholar
  81. 81.
    Churg JC, Strauss L. Allergic granulomatosis, allergic angiitis and periarteritis nodosa. Am J Pathol. 1951;27:277–301.PubMedGoogle Scholar
  82. 82.
    Finan MC, Winkelmann RK. The cutaneous extravascular necrotizing granuloma (Churg-Strauss granuloma) and systemic disease: a review of 27 cases. Medicine (Baltimore). 1983;62:142–58.Google Scholar
  83. 83.
    Hauser T, Mahr A, Metzler C, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax. 2008;63:677–82.PubMedGoogle Scholar
  84. 84.
    Weller PF, Plaut M, Taggart V, Trontell A. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol. 2001;108:175–83.PubMedGoogle Scholar
  85. 85.
    Tatsis E, Schnabel A, Gross WL. Interferon-a treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med. 1998;129:370–4.PubMedGoogle Scholar
  86. 86.
    Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis. 2006;65:557–9.PubMedGoogle Scholar
  87. 87.
    Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford). 2008;47:1104–5.Google Scholar
  88. 88.
    Jennings CA, King Jr TE, Tuder R, Cherniack RM, Schwarz MI. Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis. Am J Respir Crit Care Med. 1997;155: 1101–9.PubMedGoogle Scholar
  89. 89.
    Glover MU, Muniz J, Bessone L, Carta M, Casellas J, Maniscalco BS. Pulmonary artery obstruction due to giant cell arteritis. Chest. 1987;91:924–5.PubMedGoogle Scholar
  90. 90.
    Machado EB, Michet CJ, Ballard DJ, et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum. 1988;31:745–9.PubMedGoogle Scholar
  91. 91.
    Larson TS, Hall S, Hepper NGG, Hunder GG. Respiratory tract symptoms as a clue to giant cell arteritis. Ann Intern Med. 1984;101:594–7.PubMedGoogle Scholar
  92. 92.
    Bradley JD, Pinals RS, Blumenfeld HB, Poston WM. Giant cell arteritis with pulmonary nodules. Am J Med. 1984;77:135–40.PubMedGoogle Scholar
  93. 93.
    Zenone T, Souquet PJ, Bohas C, Vital Durand D, Bernard JP. Unusual manifestations of giant cell arteritis: pulmonary nodules, cough, conjunctivitis and otitis with deafness. Eur Respir J. 1994;7: 2252–4.PubMedGoogle Scholar
  94. 94.
    Blockmans D, Knockaert D, Bobbaers H. Giant cell arteritis can be associated with T4-lymphocytic alveolitis. Clin Rheumatol. 1999;18:330–3.PubMedGoogle Scholar
  95. 95.
    Roddy E, Summers G, Chaudry Z, Bateman R. Follicular bronchiolitis, an unusual cause of haemoptysis in giant cell arteritis. Clin Rheumatol. 2006;25:433–5.PubMedGoogle Scholar
  96. 96.
    Small P, Brisson M-L. Wegener’s granulomatosis presenting as termporal arteritis. Arthritis Rheum. 1991;34:220–3.PubMedGoogle Scholar
  97. 97.
    Nishino H, DeRemee RA, Rubino FA, Parisi JE. Wegener’s granulomatosis associated with vasculitis of the temporal artery: report of five cases. Mayo Clin Proc. 1993;68:115–21.PubMedGoogle Scholar
  98. 98.
    Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310–8.PubMedGoogle Scholar
  99. 99.
    Seo P, Stone JH. Large-vessel vasculitis. Arthritis Rheum. 2004;51:128–39.PubMedGoogle Scholar
  100. 100.
    Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore). 2009;88:221–6.Google Scholar
  101. 101.
    Lupi E, Sanchez G, Horwitz S, Gutierrez E. Pulmonary artery involvement in Takayasu’s arteritis. Chest. 1975;67:69–74.PubMedGoogle Scholar
  102. 102.
    Takahashi K, Honda M, Furuse M, Yanagisawa M, Saitoh K. CT findings of pulmonary parenchyma in Takayasu arteritis. J Comput Assist Tomogr. 1996;20:742–8.PubMedGoogle Scholar
  103. 103.
    Yamada I, Nakagawa T, Himeno Y, Kobayashi Y, Numano F, Shibuya H. Takayasu arteritis: diagnosis with breath-hold contrast-enhanced three- dimensional MR angiography. J Magn Reson Imaging. 2000;11:481–7.PubMedGoogle Scholar
  104. 104.
    Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994;37:578–82.PubMedGoogle Scholar
  105. 105.
    Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50:2296–304.PubMedGoogle Scholar
  106. 106.
    Miyata T, Ohara N, Shigematsu H, et al. Endovascular stent graft repair of aortopulmonary fistula. J Vasc Surg. 1999;29:557–60.PubMedGoogle Scholar
  107. 107.
    Liang P, Tan-Ong M, Hoffman GS. Takayasu’s arteritis: vascular interventions and outcomes. J Rheumatol. 2004;31:102–6.PubMedGoogle Scholar
  108. 108.
    Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007;56:1000–9.PubMedGoogle Scholar
  109. 109.
    Efthimiou J, Johnston C, Spiro SG, Turner-Warwick M. Pulmonary disease in Behçet’s syndrome. Q J Med. 1986;58:259–80.PubMedGoogle Scholar
  110. 110.
    Raz I, Okon E, Chajek-Shaul T. Pulmonary manifestations in Behçet’s syndrome. Chest. 1989;95: 585–9.PubMedGoogle Scholar
  111. 111.
    Winer-Muram HT, Gavant ML. Pulmonary CT findings in Behçet’s disease. J Comput Assist Tomogr. 1989;13:346–7.PubMedGoogle Scholar
  112. 112.
    Tunaci M, Ozkorkmaz B, Tunaci A, Gul A, Engin G, Acunas B. CT findings of pulmonary artery aneurysms during treatment for Behcet’s disease. AJR Am J Roentgenol. 1999;172:729–33.PubMedGoogle Scholar
  113. 113.
    Berkmen T. MR angiography of aneurysms in Behcet disease: a report of four cases. J Comput Assist Tomogr. 1998;22:202–6.PubMedGoogle Scholar
  114. 114.
    Uzun O, Akpolat T, Erkan L. Pulmonary vasculitis in Behcet disease: a cumulative analysis. Chest. 2005;127:2243–53.PubMedGoogle Scholar
  115. 115.
    Kalluri R, Wilson CB, Weber M, et al. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. J Am Soc Nephrol. 1995;6:1178–85.PubMedGoogle Scholar
  116. 116.
    Weber M, Pullig O, Kohler H. Distribution of Goodpasture antigens within various human basement membranes. Nephrol Dial Transplant. 1990;5:87–93.PubMedGoogle Scholar
  117. 117.
    Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet. 1983;2:1390–3.PubMedGoogle Scholar
  118. 118.
    Dunckley H, Chapman JR, Burke J, et al. HLA-DR and -DQ genotyping in anti-GBM disease. Dis Markers. 1991;9:249–56.PubMedGoogle Scholar
  119. 119.
    Herody M, Bobrie G, Gouarin C, Grunfeld JP, Noel LH. Anti-GBM disease: predictive value of clinical, histological and serological data. Clin Nephrol. 1993;40:249–55.PubMedGoogle Scholar
  120. 120.
    Litwin CM, Mouritsen CL, Wilfahrt PA, Schroder MC, Hill HR. Anti-glomerular basement membrane disease: role of enzyme-linked immunosorbent assays in diagnosis. Biochem Mol Med. 1996;59: 52–6.PubMedGoogle Scholar
  121. 121.
    Short AK, Esnault VLM, Lockwood CM. Anti-neutrophil cytoplasm antibodies and anti-glomerular basement membrane antibodies: two coexisting distinct autoreactivities detectable in patients with rapidly progressive glomerulonephritis. Am J Kidney Dis. 1995;26:439–45.PubMedGoogle Scholar
  122. 122.
    Weber MFA, Andrassy K, Pullig O, Koderisch J, Netzer K. Antineutrophil-cytoplasmic antibodies and antiglomerular basement membrane antibodies in Goodpasture’s syndrome and in Wegener’s granulomatosis. J Am Soc Nephrol. 1992;2:1227–34.PubMedGoogle Scholar
  123. 123.
    Bosch X, Mirapeix E, Font J, et al. Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol. 1991;36:107–13.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Pulmonary and Critical Care MedicineMayo ClinicRochesterUSA

Personalised recommendations